Results 31 to 40 of about 8,885 (125)

ICSH Recommendations for Monocyte Cell Lineage Morphologic Identification, Nomenclature Harmonization, and Utilization as a Biomarker

International Journal of Laboratory Hematology, Volume 48, Issue 1, Page 12-25, February 2026.
ABSTRACT Monocytes are key components of the Mononuclear Phagocyte System, crucial in immune defense, inflammation, and tissue repair. Accurate identification and classification of monocyte lineage cells are essential for diagnosing both reactive and clonal hematologic disorders.
Gina Zini, Yoon Hwan Chang, Giuseppe d'Onofrio, John Frater, Ulrich Germing, Anna Merino, Olga Pozdnyakova, David Ross, Claudio Romulo Siqueira Filho, Akiyoshi Takami, Erber Wendy   +10 more
wiley   +1 more source

DNA methyltransferase inhibitors in hematological malignancies and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 433-461, 15 January 2026.
Abstract Epigenetic modifications such as DNA methylation play a fundamental role in oncogenesis and the progression of neoplasms neoplasias. DNA methyltransferase inhibitors (DNMTi) constitute a family of therapeutic agents that impede the methylation at the 5‐position on cytosine nucleotides, thereby modulating the epigenetic regulation of tumor ...
Valentin Wenger, Guillermo Garcia‐Manero, Robert Zeiser, Michael Lübbert   +3 more
wiley   +1 more source

Differential Diagnoses of Systemic Mastocytosis in Routinely Processed Bone Marrow Biopsy Specimens: A Review [PDF]

, 2010
Diagnosis of systemic mastocytosis (SM) is mainly based on the morphological demonstration of compact mast cell infiltrates in various tissue sites. In almost all patients such infiltrates are detected in the bone marrow.
Horny, H. -P., Sotlar, K., Valent, P.
core   +1 more source

Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
Application of synthetic lethality screening in drug resistance models. Abstract Background and Rationale Synthetic lethality (SL)‐based strategies hold significant promise for overcoming therapeutic resistance, a critical bottleneck in cancer treatment where cancer cells evade anticancer therapies, leading to diminished efficacy or treatment failure ...
Junyan Li, Liyuan Zhang, Yan Shang, Juan Liu, Hailong Zhao   +4 more
wiley   +1 more source

Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy

HemaSphere, Volume 10, Issue 1, January 2026.
ABSTRACT The B‐cell lymphoma 2 (BCL‐2) inhibitor venetoclax (VEN) in combination with hypomethylating agents (HMAs) has improved treatment outcomes for acute myeloid leukemia (AML) patients unfit for intensive chemotherapy and is increasingly used in the relapsed/refractory setting. However, primary resistance remains a significant challenge, affecting
Ida Vänttinen, Joseph Saad, Tanja Ruokoranta, Sari Kytölä, Guangrong Qin, Bahar Tercan, Pia Ettala, Anu Partanen, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Mikko Manninen, Peter J. M. Valk, Gerwin Huls, Vésteinn Thorsson, Caroline A. Heckman, Mika Kontro, Heikki Kuusanmäki   +17 more
wiley   +1 more source

Utility and Safety of Romiplostim in Pediatric Allogeneic Stem Cell Transplantation

Pediatric Transplantation, Volume 29, Issue 8, December 2025.
ABSTRACT Background The use of romiplostim, a thrombopoietin agonist, has increased in the last decade for the treatment of immune mediated thrombocytopenia and severe aplastic anemia. Its utility has been explored in the management of delayed platelet engraftment and secondary platelet failure during stem cell transplant (SCT), but its use has ...
Srividhya Senthil, Abdul Moothedath, Jane Elizabeth Potter, Heather Mcgrath Wilkinson, Eden Whiteside, Ramya Nataraj, Omima Mustafa, Claire Horgan, Denise Bonney, Sarah Brett, Rob Wynn   +10 more
wiley   +1 more source

Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. [PDF]

, 2015
Somatic mutations in the spliceosome gene ZRSR2-located on the X chromosome-are associated with myelodysplastic syndrome (MDS). ZRSR2 is involved in the recognition of 3'-splice site during the early stages of spliceosome assembly; however, its precise ...
Ganser, Arnold, Grossmann, Vera, Haferlach, Torsten, Kanojia, Deepika, Koeffler, H Phillip, Kohlmann, Alexander, Li, Jia, Madan, Vikas, Miyano, Satoru, Ogawa, Seishi, Okamoto, Ryoko, Sanada, Masashi, Sato-Otsubo, Aiko, Shiraishi, Yuichi, Sundaresan, Janani, Thol, Felicitas, Yang, Henry   +16 more
core   +2 more sources

Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis [PDF]

, 2017
Chronic lymphocytic leukemia (CLL) is characterized by the expansion of malignant CD5(+) B lymphocytes in blood, bone marrow and lymphoid organs. CD1d-restricted invariant Natural Killer T (iNKT) cells are innate-like T lymphocytes strongly implicated in
Azzimonti, Laura, Bellone, Matteo, Bertilaccio, Maria Teresa, Caligaris Cappio, Federico, Capri, Miriam, Casorati, Giulia, de Lalla, Claudia, Delfanti, Gloria, Dellabona, Paolo, DI NAPOLI, Arianna, Doglioni, Claudio, Franceschi, Claudio, Ghia, Paolo, Gorini, Francesca, Gulino, Alessandro, Ranghetti, Pamela, Scarfò, Lydia, Scielzo, Cristina   +17 more
core   +1 more source

The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances

MedComm, Volume 6, Issue 10, October 2025.
Immunotherapy, serving as a crucial breakthrough of precision medicine in the field of cancer treatment, among which immune checkpoint inhibitors (ICIs) have witnessed the most extensive application. This review systematically investigates the challenges, advancements, and future directions of ICIs in tumor treatment.
Hengyi Chen, Hongling Yang, Lu Guo, Qingxiang Sun   +3 more
wiley   +1 more source

Co‐operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity

British Journal of Haematology, Volume 207, Issue 4, Page 1289-1300, October 2025.
A proposed model of Setd2 deficiency and KrasG12D/+ mutation synergism in the pathogenesis of juvenile myelomonocytic leukaemia (JMML). KrasG12D/+ mutation instigates constitutive activation of the RAS‐ERK1/2 signalling pathway, and Setd2 ablation in the KrasG12D/+ mutant background further hyperactivates the RAS‐ERK1/2 signalling pathway, leading to ...
Gustave Munyurangabo, Linlin Zhang, Ying Zhou, Peihua Zhang, Xiao Yu, Dou Qu, Dan Yang, Xiaomin Ren, Hongwei Liu, Yonghong Wu, Guangyao Kong, Yi Yang   +11 more
wiley   +1 more source